By: IPP Bureau
Last updated : June 25, 2024 6:57 pm
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and specialty market, is excited to announce a new step in its collaboration with Arkema, a world leader in specialty materials, with the signature of an exclusive technology license for the manufacturing of PEKK for sale in long term implantable applications.
The two companies have partnered for 15 years, combining Arkema’s expertise and intellectual property in PEKK technology together with Seqens’ recognized know-how in the production of polymers for the pharmaceutical and life sciences markets.
PEKK is a high-performance polymer family used in aerospace and other demanding markets, commercialized by Arkema under the Kepstan trademark. Seqens’ IMPEKK materials have been specifically developed for long term medical implantable applications and could represent an alternative to existing titanium and PEEK materials. IMPEKK materials will be provided to the market by SEQENS through a global network of partners, including well-known manufacturers, 3D printing machine companies, and distributors.
“It’s an honor to partner with Arkema and benefit from their unique expertise in the technology of PEKK polymers. Relying on our strong know-how in complex chemistry for polymer synthesis and experience in PEKK manufacturing, we are committed to deliver best in class solutions, with projects already underway in Europe, USA, and Asia,” said Chiara Bergerone, MD, Seqens’ Innovative Business Unit.
It is with great pleasure that we renew and strengthen our technological relationship with Seqens successfully started 15 years ago,” said Erwoan Pezron, Member of Executive Committee and President of High Performance Business Line.